Prevention of tumors of the large intestine by celecoxib in mice.
Celecoxib (C), a COX-2 enzyme inhibitor, was administered at a 0.1% dose level in the diet of female Swiss Webster CFW outbred mice for life. The mice also received 1,2-dimethylhydrazine dihydrochloride (1,2-DMH) as 10 weekly subcutaneous injections at 20 microg/g body weight. The number of animals with large intestinal cancer and the total number of these cancers were 30 and 321 in the 1,2-DMH-treated group, while the corresponding figures in the C and 1,2-DMH-treated group were 29 and 156. This difference is statistically highly significant. The literature contains a limited number of publications concerning the cancer chemopreventive activity of C, particularly in mice. The present work, thus, provides additional proof in this field of interest.
The Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.
Melissa
M
Coles
Bela
B
Toth
D000230:Adenocarcinoma / Q000139:chemically induced / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D000236:Adenoma / Q000139:chemically induced / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D000284:Administration, Oral; D000818:Animals; D021461:Animals, Outbred Strains; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004032:Diet; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D005260:Female; D007093:Imidazoles / Q000633:toxicity; D007414:Intestinal Neoplasms / Q000139:chemically induced / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D008136:Longevity / Q000187:drug effects; D051379:Mice; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D015996:Survival Rate
D016588:Anticarcinogenic Agents; D016861:Cyclooxygenase Inhibitors; D007093:Imidazoles; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; C032654:1,2-dimethylimidazole